Stock Analysis
- Australia
- /
- Personal Products
- /
- ASX:S66
Star Combo Pharma Full Year 2024 Earnings: EPS: AU$0.01 (vs AU$0.03 loss in FY 2023)
Star Combo Pharma (ASX:S66) Full Year 2024 Results
Key Financial Results
- Revenue: AU$26.5m (up 7.0% from FY 2023).
- Net income: AU$747.3k (up from AU$4.00m loss in FY 2023).
- Profit margin: 2.8% (up from net loss in FY 2023). The move to profitability was primarily driven by lower expenses.
- EPS: AU$0.01 (up from AU$0.03 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Star Combo Pharma shares are up 25% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Star Combo Pharma has 2 warning signs (and 1 which is significant) we think you should know about.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ASX:S66
Star Combo Pharma
Engages in the manufacturing and distribution of health food products and nutritional supplements in Australia and China.